4.7 (652) In stock
Just as Novartis’ C-suite appeared to have stabilized amid a major overhaul of the company, the Swiss pharma is losing its international markets leader and getting rid of its chief commercial offic | Just as Novartis’ C-suite appeared to have stabilized amid a major overhaul of the company, the Swiss pharma is losing its international markets leader and getting rid of its chief commercial officer title.
09.06.23 Novartis replaces outgoing exec, scraps CCO title; J&J's Rybrevant posts win in large lung cancer field - Questex
SEC Filing ID 0001438533-24-000005
Novartis names new board member after international boss steps
Novartis is losing its chief commercial officer - STAT
Novartis to lay off another 103 people at US HQ
ESMO Guidance for Reporting Oncology real-World evidence (GROW) - ESMO Real World Data and Digital Oncology
Theme and final dates announced for the 2023 Brain Innovation Days - Brain Innovation Days
The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians – Poster Session (P001 – P182)
Novartis: Novartis names new board member after international boss
Prioritizing the needs of patients
Frontiers Cell and gene therapy regulatory, pricing, and reimbursement framework: With a focus on South Korea and the EU
NOVARTIS AG - 8.1 For a list of all of our principal Group subsidiaries and associated companies, see “Item 18. Financial Statements—Note 32. Principal Group subsidiaries and associated companies.”* - 20-F - February 02, 2022
